Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus octreotide versus octreotide alone for polycystic liver volume reduction
NL-OMON32654Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2010
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of everolimus and octreotide in Polycystic liver disease (PLD), sponsored by Radboud University Medical Center. Primary endpoint: Reduction of liver volume from baseline to 48 weeks. Started Jun 2010; status: active, not recruiting.
02
Drugs
everolimusoctreotide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NL-OMON32654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32654.